Pharma Focus Asia
KP - Choose our fully recyclable blister films

Abbisko Therapeutics Discovered Novel CSF-1R Inhibitor Pimicotinib (ABSK021)

Abbisko Therapeutics discovered novel CSF-1R inhibitor Pimicotinib(ABSK021) for the treatment of tenosynovial giant cell tumour (TGCT) patients not responding to surgery.

Pimicotinib is the first new generation CSF-1R drug candidate in the world. It is a novel, oral, highly selective and highly potent small molecule inhibitor of CSF-1R. Several studies have shown that blocking the CSF-1R signalling pathway can effectively modulate and alter macrophage functions, and has the potential to treat many macrophage-dependant human diseases. Pimicotinib is currently being studied for the treatment of tenosynovial giant cell tumour (TGCT) and cGVHD , and is being evaluated for, other indications.

Pimicotinib showed significant antitumor efficacy in a phase Ib trial in patients with TGCT, resulting a preliminary ORR of 68.0 per cent and favourable safety profile.

TGCT, a pigmented villonodular synovitis, is a locally aggressive neoplasm affecting synovial joints, mucous sacs, and tendon membranes, resulting in swelling, pain, stiffness, and decreased activity of the affected joints which seriously affect the patient's quality of life.

US Food and Drug Administration (FDA) grants breakthrough device designation for its CSF-1R inhibitor Pimicotinib (ABSK021).

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024